caprylates has been researched along with camptothecin in 1 studies
| Studies (caprylates) | Trials (caprylates) | Recent Studies (post-2010) (caprylates) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 5,061 | 100 | 2,339 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | caprylates (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaul, SC; Liu, M; Miyako, E; Nishikawa, M; Takahashi, J; Tei, T; Wadhawa, R; Yu, Y; Zhang, M | 1 |
1 other study(ies) available for caprylates and camptothecin
| Article | Year |
|---|---|
Self-assembled nanodiamond supraparticles for anticancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Caprylates; Cell Membrane Permeability; Drug Carriers; Female; Fibroblasts; Fluorocarbons; HeLa Cells; HT29 Cells; Humans; Mice, Inbred BALB C; Nanodiamonds; Nanomedicine; Neoplasms, Experimental; Phospholipids; Polyethylene Glycols | 2018 |